The discovery of endothelium-dependent contraction: The legacy of Paul M. Vanhoutte

Pharmacological Research

Volumn 63, Issue 6, 2011, Pages 455-462

  Barton, Matthias ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Blood pressure; Endothelin; Endothelium; Nitric oxide; Prostanoids; Vasoactive factors; Vasoconstriction

Indexed keywords

ACETYLCHOLINE; AVOSENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; SITAXSENTAN;

BLOOD VESSEL TONE; CELL STIMULATION; DRUG FATALITY; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; LIVER FAILURE; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SEQUENCE ANALYSIS; VASOCONSTRICTION; VASODILATATION;

EID: 79958031263     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.02.013     Document Type: Article

References (113)

1. Rodbell M. Signal transduction: evolution of an idea. Nobel lecture, December 8, 1994, http://profiles.Nlm.Nih.Gov/gg/views/alphachron/date/10018; 1994 [accessed 12.02.11].
2. Furchgott RF. Introduction to EDRF research. J Cardiovasc Pharmacol 1993;22:S1-2.
3. Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Nobel lecture, December 8, 1998. Biosci Rep 1999;19:235-51.
4. Cryer A. Scale and diversity of interaction at the vascular endothelium. Biochemical interactions of the endothelium. Amsterdam: Elsevier; 1983.
5. Barton M, Haudenschild C. Endothelium and atherogenesis: endothelial therapy revisited. J Cardiovasc Pharmacol 2001;38(Suppl. 2):S23-25.
6. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009;196:193-222.
7. Vanhoutte PM. How we learned to say NO. Arterioscler Thromb Vasc Biol 2009;29:1156-60.
8. Vane JR, Bunting S, Moncada S. Prostacyclin in physiology and pathophysiology. Int Rev Exp Pathol 1982;23:161-207.
9. Dusting GJ, Moncada S, Vane JR. Prostacyclin (pgx) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins 1977;13:3-15. (Pubitemid 8030252)
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-5.
11. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-9.
12. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6. (Pubitemid 11169009)
13. Nilius B, Serban DN, Vanhoutte PM, Robert F. Furchgott and his heritage: endothelial vasomotor control. Pflugers Arch 2010;459:785-6.
14. Heistad DD. Endothelial function in the time of the giants. J Cardiovasc Pharmacol 2008;52:385-92.
15. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (the Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291:H985-1002.
16. Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 2009;122:140-9.
17. Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad! J Physiol 2008;586:5295-304.
18. Traupe T, Ortmann J, Munter K, Barton M. Endothelial therapy of atherosclerosis and its risk factors. Curr Vasc Pharmacol 2003;1:111-21.
19. De Mey JG, Vanhoutte PM. Contribution of the endothelium to the response to anoxia in the canine femoral artery. Arch Int Pharmacodyn Ther 1981;253:325-6. (Pubitemid 12200110)
20. De Mey JG, Vanhoutte PM. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 1982;51:439-47.
21. Jelliffe RW. Dilator and constrictor effects of acetylcholine on isolated rabbit aortic chains. J Pharmacol Exp Ther 1962;135:349-53.
22. Furchgott RF, Davidson D, Lin C. Conditions which determine whether muscarinic agonists contract or relax rabbit aortic rings and strips. Blood Vessels 1979;16:213-4. (Pubitemid 9210773)
23. De Mey JG, Vanhoutte PM. Role of the intima in cholinergic and purinergic relaxation of isolated canine femoral arteries. J Physiol 1981;316:347-55.
24. Furchgott RF. A research trail over half a century. Annu Rev Pharmacol Toxicol 1995;35:1-27.
25. Lacroix E, Vanhoutte P, Leusen I. The phosphorylase activity of the myocardium under the influence of reserpine. Arch Int Pharmacodyn Ther 1962;138:329-33.
26. Vanhoutte PM, Shepherd JT. Venous relaxation caused by acetylcholine acting on the sympathetic nerves. Circ Res 1973;32:259-67.
27. Vanhoutte PM. Inhibition by acetylcholine of adrenergic neurotransmission in vascular smooth muscle. Circ Res 1974;34:317-26.
28. Toda N. The action of vasodilating drugs on isolated basilar, coronary and mesenteric arteries of the dog. J Pharmacol Exp Ther 1974;191:139-46.
29. Furchgott RF. The pharmacology of vascular smooth muscle. Pharmacol Rev 1955;7:183-265.
30. Chand N, Altura BM. Acetylcholine and bradykinin relax intrapulmonary arteries by acting on endothelial cells: role in lung vascular diseases. Science 1981;213:1376-9. (Pubitemid 12243631)
31. Buonassisi V, Venter JC. Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proc Natl Acad Sci USA 1976;73:1612-6.
32. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983;306:174-6. (Pubitemid 14228339)
33. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may bemediated through cgmp. Circ Res 1983;52:352-7. (Pubitemid 13158751)
34. Venter JC. Genome-sequencing anniversary. The human genome at 10: successes and challenges. Science 2011;331:546-7.
35. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291:1304-51. (Pubitemid 32173090)
36. Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 2010;329:52-6.
37. Furchgott RF. The discovery of endothelium-dependent relaxation. Circulation 1993;87(Suppl. V):V3-8.
38. Martin W, Robert F. Furchgott, noble laureate (1916-2009) - a personal reflection. Br J Pharmacol 2009;158:633-7.
39. Rubanyi G, Vanhoutte PM. Endothelium-removal decreases relaxations of canine coronary arteries caused by beta-adrenergic agonists and adenosine. J Cardiovasc Pharmacol 1985;7:139-44. (Pubitemid 15162256)
40. Cohen RA, Shepherd JT, Vanhoutte PM. 5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries. Am J Physiol 1983;245:H1077-80.
41. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
42. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994;23:1121-31.
43. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-14.
44. Rubanyi GM, Vanhoutte PM. Nature of endothelium-derived relaxing factor: are there two relaxing mediators? Circ Res 1987;61:II61-7.
45. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-24. (Pubitemid 18069063)
46. Vanhoutte PM. Endothelium-dependent hyperpolarizations: the history. Pharmacol Res 2004;49:503-8. (Pubitemid 38338659)
47. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. Edhf: bringing the concepts together. Trends Pharmacol Sci 2002;23:374-80.
48. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium-dependent responses. Pflugers Arch 2010;459:881-95.
49. De Mey JG, Vanhoutte PM. Anoxia and endothelium-dependent reactivity of the canine femoral artery. J Physiol 1983;335:65-74.
50. Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J Physiol 1985;364:45-56.
51. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248:C550-6.
52. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5. (Pubitemid 18090241)
53. Vanhoutte PM, Katusic ZS. Endothelium-derived contracting factor: endothelin and/or superoxide anion? Trends Pharmacol Sci 1988;9:229-30.
54. Vanhoutte PM, Auch-Schwelk W, Boulanger C, Janssen PA, Katusic ZS, Komori K, et al. Does endothelin-1 mediate endothelium-dependent contractions during anoxia? J Cardiovasc Pharmacol 1989;13(Suppl. 5):S124-8, discussion S142.
55. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-827.
56. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989;257:H33-37.
57. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-6. (Pubitemid 16097810)
58. Hieda HS, Gomez-Sanchez CE. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin ii do not. Life Sci 1990;47:247-51. (Pubitemid 20243805)
59. Rakugi H, Tabuchi Y, Nakamaru M, Nagano M, Higashimori K, Mikami H, et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 1990;169:973-7. (Pubitemid 20220715)
60. Gertler JP, Ocasio VH. Endothelin production by hypoxic human endothelium. J Vasc Surg 1993;18:178-82, discussion 182-174.
61. Kahler J, Ewert A, Weckmuller J, Stobbe S, Mittmann C, Koster R, et al. Oxidative stress increases endothelin-1 synthesis inhumancoronary artery smooth muscle cells. J Cardiovasc Pharmacol 2001;38:49-57. (Pubitemid 32634989)
62. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, et al. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 2000;32:1429-37.
63. Knappe D, Sill B, Tharun B, Koester R, Baldus S, Muenzel T, et al. Endothelin-1 in humans is increased by oxygen-derived radicals ex vivo and in vivo. J Investig Med 2007;55:306-14. (Pubitemid 350205425)
64. Jones RD, Wanstall JC, Gambino A, Morice AH. The effect of the endothelin ET(A) receptor antagonist ci-1020 on hypoxic pulmonary vasoconstriction. Eur J Pharmacol 1999;374:367-75. (Pubitemid 29313449)
65. Miller VM, Vanhoutte PM. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase. Am J Physiol 1985;248:H432-7.
66. Taddei S, Vanhoutte PM. Endothelium-dependent contractions to endothelin in the rat aorta are mediated by thromboxane A2. J Cardiovasc Pharmacol 1993;22:S328-31.
67. Vanhoutte PM. COX-1 and vascular disease. Clin Pharmacol Ther 2009;86:212-5.
68. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986;8:344-8. (Pubitemid 16042204)
69. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, et al. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 2000;11:835-45.
70. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002;20:2239-45. (Pubitemid 35388243)
71. Vanhoutte PM. Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension 2011;57:526-31.
72. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: Cox-1 and cox-2 products. Br J Pharmacol 2011.
73. Tang EH, Vanhoutte PM. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol Genomics 2008;32:409-18. (Pubitemid 351328564)
74. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1986;236:339-43. (Pubitemid 16184223)
75. O'Brien RF, Robbins RJ, McMurtry IF. Endothelial cells in culture produce a vasoconstrictor substance. J Cell Physiol 1987;132:263-70. (Pubitemid 17151479)
76. Rubanyi GM. The discovery of endothelin: the power of bioassay and the role of serendipity in the discovery of endothelium-derived vasoactive substances. Pharmacol Res 2011.
77. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008;86:485-98.
78. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cdna encoding an endothelin receptor. Nature 1990;348:730-2. (Pubitemid 120015147)
79. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cdna encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-5. (Pubitemid 120015148)
80. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, et al. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010;56:121-8.
81. Vanhoutte PM. Say NO to ET. J Auton Nerv Syst 2000;81:271-7. (Pubitemid 30408509)
82. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Münter K, Lüscher TF. Endothelin ETA receptor blockade restores no-mediated endothelial function and inhibits atherosclerosis in apoe-deficient mice. Proc Natl Acad Sci USA 1998;95:14367-72.
83. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-6. (Pubitemid 28135337)
84. Best PJ, McKenna CJ, Hasdai D, Holmes Jr DR, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999;99:1747-52. (Pubitemid 29162489)
85. Taner CB, Severson SR, Best PJ, Lerman A, Miller VM. Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. J Appl Physiol 2001;90:816-20. (Pubitemid 32171363)
86. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958-66.
87. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, et al. Endothelin receptor subtype b mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-73. (Pubitemid 23127334)
88. Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, Schiffrin EL. Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 2010;28:1243-51.
89. Amiri F, Paradis P, Reudelhuber TL, Schiffrin EL. Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J Hypertens 2008;26:1102-9. (Pubitemid 351670501)
90. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004;110:2233-40. (Pubitemid 39372507)
91. Leung JW, Chung SS, Chung SK. Endothelial endothelin-1 over-expression using receptor tyrosine kinase tie-1 promoter leads to more severe vascular permeability and blood brain barrier breakdown after transient middle cerebral artery occlusion. Brain Res 2009;1266:121-9.
92. Leung JW, Ho MC, Lo AC, Chung SS, Chung SK. Endothelial cell-specific over-expression of endothelin-1 leads to more severe cerebral damage following transient middle cerebral artery occlusion. J Cardiovasc Pharmacol 2004;44(Suppl1):S293-300.
93. Yeung PK, Lo AC, Leung JW, Chung SS, Chung SK. Targeted overexpression of endothelin-1 in astrocytes leads to more severe cytotoxic brain edema and higher mortality. J Cereb Blood Flow Metab 2009;29:1891-902.
94. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-40.
95. Webb DJ. Endothelin receptors cloned, endothelin converting enzyme characterized and pathophysiological roles for endothelin proposed. Trends Pharmacol Sci 1991;12:43-6.
96. Clozel M, Breu V, Burri K, Cassal J-M, Fischli W, Gray GA, et al. Pathophysiologic role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61. (Pubitemid 23339883)
97. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" Class of drug. Exp Biol Med (Maywood) 2006;231:653-95.
98. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-19. (Pubitemid 351415492)
99. Webb DJ. Dorado: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 2010;56:806-7.
100. Clozel M. Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research. Sci Transl Med 2011;3:67cm62.
101. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64.
102. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-35.
103. Pringent B. Thelin (sitaxsentan sodium) - worldwide product withdrawal - for health professionals: http://hc-sc.Gc.Ca/dhp-mps/medeff/advisoriesavis/prof/ -2010/thelin-2-hpc-cps-eng.Php [accessed 12.02.11].
104. Davenport AP, Maguire JJ. Of mice and men: advances in endothelin research and first antagonist gains fda approval. Trends Pharmacol Sci 2002;23:155-7. (Pubitemid 34270588)
105. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
106. MacDonald I. Professor Paul M. Vanhoutte - portrait of an extraordinary medical researcher. Interview by Iona Macdonald, MA. Eur Heart J 2009;30:1020-2.
107. Ku DD, Feinmark SJ. Paul M. Vanhoutte distinguished lectureship award. J Cardiovasc Pharmacol 2008;52:383-4.
108. Duckles SP. Happy 70th birthday, Paul M. Vanhoutte. Pharmacol Int 2010;75:18. www.iuphar.org/pdf/Pharmacology-International-2010-December.pdf.
109. Vanhoutte PM. In memoriam: Robert F. Furchgott. J Cardiovasc Pharmacol 2009;54:179.
110. Warner TD, Vane JR. Pharmacology. ET touches down in Houston. Nature 1993;362:497-8.
111. www.endothelin-conferences.org/Cambridge2011 [accessed 12.02.11).
112. Paul M. Vanhoutte Research Symposium. http://asvb2010.smugmug.com/pmv- research-symposium [accessed 12.02.11].
113. Vanhoutte PM. The endothelium: thirty years of surprises [article in French]. Ann Cardiol Angéiol (Paris) 2008;57:133-5.